Acotiamide, a novel gastroprokinetic for the treatment of patients with functional dyspepsia: Postprandial distress syndrome

Ege Altan, Tatsuhiro Masaoka, Ricard Farré, Jan Tack

Research output: Contribution to journalArticle

28 Citations (Scopus)


Functional dyspepsia (FD) is a highly prevalent condition with major socioeconomic and healthcare impact. To date, no pharmacological treatment for FD has been approved. The Rome consensus proposed to subdivide FD into postprandial distress syndrome (PDS), characterized by meal-related symptoms and epigastric pain syndrome, characterized by pain and burning. Acotiamide (Z-338 or YM443) is a new drug, developed for the treatment of FD. Acotiamide enhances acetylcholine release from enteric neurons through muscarinic receptor antagonism and acetycholinesterase inhibition, thereby enhancing gastric emptying and gastric accommodation. Acotiamide was evaluated in FD in clinical studies in Europe, Japan and the USA, beneficial effects were observed for the PDS symptoms of postprandial fullness and early satiation, with a dose of 100 mg three-times a day. A 4-week placebo-controlled Phase III study in PDS patients in Japan confirmed efficacy of acotiamide in relieving postprandial fullness, early satiation and upper abdominal bloating.

Original languageEnglish
Pages (from-to)533-544
Number of pages12
JournalExpert Review of Gastroenterology and Hepatology
Issue number5
Publication statusPublished - 2012 Sep
Externally publishedYes



  • acotiamide
  • early satiation
  • functional dyspepsia
  • gastric accommodation
  • gastric emptying
  • postprandial fullness
  • randomized-controlled trial

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this